Moreover, it may be suggested that urethral smooth muscles become more sensitive to alpha-adrenergic receptor stimulation before puberty
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Urinary side effects of atomoxetine are extremely rare, especially in children.
📊
Key Findings & Data:We report the presentation of acute urinary retention in an 8-year-old boy with attention deficit hyperactivity disorder (ADHD).
💡
Conclusion & Impact:Moreover, it may be suggested that urethral smooth muscles become more sensitive to alpha-adrenergic receptor stimulation before puberty
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Urinary side effects of atomoxetine are extremely rare, especially in children. We report the presentation of acute urinary retention in an 8-year-old boy with attention deficit hyperactivity disorder (ADHD). To the best of our knowledge, this is the first case of a school-aged child experiencing urinary retention due to an increased dose of atomoxetine. We propose that noradrenergic systems in the urinary tract, possibly precipitated by a higher than usual initial dose of atomoxetine, may have been over-activated. Moreover, it may be suggested that urethral smooth muscles become more sensitive to alpha-adrenergic receptor stimulation before puberty
🔖
Cite This Article
IPEK, H., MUTLU, C., TANJU, I. A., YORBİK, O. (2022). Acute urinary retention associated with increased dose of atomoxetine in a child: a case report. Klinik Psikofarmakoloji Bülteni, Cilt: 25 - Sayı: 3, 299–301. https://ajindex.com/articles/573952
McDonagh MS, Peterson K, Thakurta S, Low A. Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report [Internet]. SourcePortland (OR): Oregon Health & Science University, 2011. Available from: http://www.ncbi.nlm.nih.gov/books/ NBK84419/pdf/TOC.pdf 2. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176. [CrossRef] 3. Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat 2006;2(4):455-66. [CrossRef] 4. Desarkar P, Sinha VK. Acute urinary retention associated with atomoxetine use. Aust N Z J Psychiatry 2006;40(10):936. [CrossRef] 5. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56(4):581-631. [CrossRef] 6. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147(Suppl.2):S25-S40. [CrossRef] 7. Takahashi S, Moriyama N, Yamazaki R, Kawabe K. Urodynamic analysis of age-related changes of alpha 1-adrenoceptor responsiveness in female beagle dogs. J Urol 1996;156(4):1485-8. [CrossRef] 8. Camporeale A, Day KA, Ruff D, Arsenault J, Williams D, Kelsey DK. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf 2013;36(8):663-71. [CrossRef] 9. Borade S, Bhirud M, Kadam K. Reboxetine-induced urinary hesitancy. Indian J Psychiatry 2005;47(2):130. [CrossRef]